Massimo Gion

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1984876/publications.pdf

Version: 2024-02-01

89 papers	5,008 citations	218677 26 h-index	88630 70 g-index
90 all docs	90 docs citations	90 times ranked	10882 citing authors

#	Article	IF	Citations
1	Biological variation and reference change value as decision criteria in clinical use of tumor biomarkers. Are they really useful?. Clinical Chemistry and Laboratory Medicine, 2022, 60, e136-e137.	2.3	2
2	Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. ESMO Open, 2022, 7, 100459.	4.5	26
3	State of the art and trends of circulating cancer biomarkers. International Journal of Biological Markers, 2020, 35, 12-15.	1.8	9
4	ELISA assay employing epitope-specific monoclonal antibodies to quantify circulating HER2 with potential application in monitoring cancerÂpatients undergoing therapy with trastuzumab. Scientific Reports, 2020, 10, 3016.	3.3	14
5	Serum Tumor Markers in Paraneoplastic Neurologic Syndromes: A Systematic Review of Guidelines. Frontiers in Neurology, 2020, 11, 607553.	2.4	2
6	BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories. Diagnostics, 2019, 9, 146.	2.6	3
7	Insufficient uptake of systematic search methods in oncological clinical practice guideline: a systematic review. BMC Medical Research Methodology, 2019, 19, 180.	3.1	4
8	Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives. Critical Reviews in Oncology/Hematology, 2019, 140, 67-72.	4.4	51
9	Shed HER2 surrogacy evaluation in primary breast cancer patients: a study assessing tumor tissue HER2 expression at both extracellular and intracellular levels. Scandinavian Journal of Clinical and Laboratory Investigation, 2019, 79, 260-267.	1.2	4
10	Preanalytical stability of [-2]proPSA in whole blood stored at room temperature before separation of serum and plasma: implications to Phi determination. Clinical Chemistry and Laboratory Medicine, 2019, 57, 521-531.	2.3	5
11	Phytosome complex of curcumin as complementary therapy of advanced pancreatic cancer improves safety and efficacy of gemcitabine: Results of a prospective phase II trial. Pharmacological Research, 2018, 132, 72-79.	7.1	104
12	Human Chorionic Gonadotropin Assays for Testicular Tumors: Closing the Gap between Clinical and Laboratory Practice. Clinical Chemistry, 2018, 64, 270-278.	3.2	23
13	Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients. BMC Cancer, 2018, 18, 651.	2.6	16
14	Indicators of inappropriate tumour marker use through the mining of electronic health records. Journal of Evaluation in Clinical Practice, 2017, 23, 895-902.	1.8	5
15	Decision making about healthcare-related tests and diagnostic test strategies. Paper 5: a qualitative study with experts suggests that test accuracy data alone is rarely sufficient for decision making. Journal of Clinical Epidemiology, 2017, 92, 47-57.	5.0	10
16	Epidemiology-Based Assessment of Tumor Marker Overordering in Breast Cancer: An Algorithm to Examine Different Disease Conditions. International Journal of Biological Markers, 2017, 32, 471-473.	1.8	2
17	Circulating Tumor Markers: A Guide to Their Appropriate Clinical Use: Comparative Summary of Recommendations from Clinical Practice Guidelines (PART 2). International Journal of Biological Markers, 2017, 32, 1-52.	1.8	13
18	Circulating Tumor Markers: A Guide to their Appropriate Clinical Use. International Journal of Biological Markers, 2017, 32, 147-181.	1.8	12

#	Article	IF	Citations
19	Appropriateness of tumor marker request: a case of study. Annals of Translational Medicine, 2017, 5, 274-274.	1.7	6
20	Need for Knowledge Translation to Improve Tumor Marker Application. International Journal of Biological Markers, 2016, 31, 331-331.	1.8	3
21	Evaluating Serum Insulin-Like Growth Factor 1 and Insulin-Like Growth Factor Binding Protein 3 as Markers in Prostate Cancer Diagnosis. International Journal of Biological Markers, 2016, 31, 317-323.	1.8	3
22	Circulating Tumor Markers: A Guide to their Appropriate Clinical use: Comparative Summary of Recommendations from Clinical Practice Guidelines (PART 1). International Journal of Biological Markers, 2016, 31, 332-367.	1.8	18
23	HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study. Gynecologic Oncology, 2016, 141, 303-311.	1.4	87
24	An epidemiology-based model as a tool to monitor the outbreak of inappropriateness in tumor marker requests: a national scale study. Clinical Chemistry and Laboratory Medicine, 2016, 54, 473-82.	2.3	19
25	Sirtuin 1 stabilization by HuR represses TNF-Î±- and glucose-induced E-selectin release and endothelial cell adhesivenessinÂvitro: relevance to human metabolic syndrome. Clinical Science, 2014, 127, 449-461.	4.3	35
26	An epidemiology-based model to estimate the rate of inappropriateness of tumor marker requests. Clinical Chemistry and Laboratory Medicine, 2014, 52, 889-97.	2.3	7
27	The Role of HE4 in Ovarian Cancer Follow-up: A Review. International Journal of Gynecological Cancer, 2014, 24, 1359-1365.	2.5	36
28	Italian consensus guidelines for the diagnostic work-up and follow-up of cystic pancreatic neoplasms. Digestive and Liver Disease, 2014, 46, 479-493.	0.9	108
29	Re: Biological variation of neuroendocrine tumor markers chromogranin A and neuron-specific enolase. Clinical Biochemistry, 2013, 46, 1145.	1.9	2
30	Evaluation of a sex hormone-binding globulin automated chemiluminescent assay. Scandinavian Journal of Clinical and Laboratory Investigation, 2013, 73, 480-484.	1.2	2
31	Design of Tumor Biomarkerâ€"Monitoring Trials: A Proposal by the European Group on Tumor Markers. Clinical Chemistry, 2013, 59, 52-59.	3.2	37
32	Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1815-24.	2.3	32
33	Inflammation Markers: New Actors in the Cancer Biomarker Tale. International Journal of Biological Markers, 2013, 28, 1-2.	1.8	0
34	Prognostic Significance of Vascular Endothelial Growth Factor Serum Determination in Women with Ovarian Cancer. ISRN Obstetrics & Gynecology, 2012, 2012, 1-11.	1.2	31
35	Androgen receptors and serum testosterone levels identify different subsets of postmenopausal breast cancers. BMC Cancer, 2012, 12, 599.	2.6	16
36	A multi-element psychosocial intervention for early psychosis (GET UP PIANO TRIAL) conducted in a catchment area of 10 million inhabitants: study protocol for a pragmatic cluster randomized controlled trial. Trials, 2012, 13, 73.	1.6	47

#	Article	IF	Citations
37	Interplay Between miR-155, AT1R A1166C Polymorphism, and AT1R Expression in Young Untreated Hypertensives. American Journal of Hypertension, 2011, 24, 241-246.	2.0	135
38	New Frontiers in Tumor Marker Studies: From Biobanking to Collaboration in Translational Research. International Journal of Biological Markers, 2011, 26, 73-74.	1.8	7
39	Development of a Website and Biobank Database for the Nanosized Cancer Polymarker Biochip Project: A Multicenter Italian Experience. International Journal of Biological Markers, 2011, 26, 197-206.	1.8	2
40	Circulating Sex Hormones and Tumor Characteristics in Postmenopausal Breast Cancer Patients. A Cross-Sectional Study. International Journal of Biological Markers, 2011, 26, 241-246.	1.8	8
41	Osteopontin, asbestos exposure and pleural plaques: a cross-sectional study. BMC Public Health, 2011, 11, 220.	2.9	5
42	Extraction methods of red blood cell membrane proteins for Multidimensional Protein Identification Technology (MudPIT) analysis. Journal of Chromatography A, 2010, 1217, 5328-5336.	3.7	26
43	Research Trends for Early Cancer Biomarker Detection in Italy: An Integrated Program in Oncology (PIO) Survey. Tumori, 2010, 96, 721-725.	1.1	0
44	Experimental validation of specificity of the squamous cell carcinoma antigen-immunoglobulin M (SCCA-IgM) assay in patients with cirrhosis. Clinical Chemistry and Laboratory Medicine, 2010, 48, 217-23.	2.3	11
45	Tumour markers requesting pattern with regards to different organizational settings in Italy: a survey of hospital laboratories. Annals of Clinical Biochemistry, 2009, 46, 316-321.	1.6	10
46	Testosterone and Biological Characteristics of Breast Cancers in Postmenopausal Women. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2942-2948.	2.5	21
47	Activated leukocyte cell adhesion molecule: A novel biomarker for breast cancer. International Journal of Cancer, 2009, 125, 9-14.	5.1	55
48	Serial determination of CEA and CA 15.3 in breast cancer follow-up: An assessment of their diagnostic accuracy for the detection of tumour recurrences. Biomarkers, 2009, 14, 130-136.	1.9	29
49	Human Kallikrein 5: An Interesting Novel Biomarker in Ovarian Cancer Patients That Elicits Humoral Response. International Journal of Gynecological Cancer, 2009, 19, 1015-1021.	2.5	19
50	Evaluation of cell-free DNA in urine as a marker for bladder cancer diagnosis. International Journal of Biological Markers, 2009, 24, 147-155.	1.8	20
51	The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysis. International Journal of Biological Markers, 2009, 24, 119-129.	1.8	6
52	Differential liquid phase proteomic analysis of the effect of selenium supplementation in LNCaP cells. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 865, 63-73.	2.3	5
53	MPA: A multiple peak alignment algorithm to perform multiple comparisons of liquidâ€phase proteomic profiles. Proteomics, 2008, 8, 250-253.	2.2	8
54	Alternative antibody for the detection of CA15-3 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the AccessÂ® BR Monitor assay on the UniCelÂ® DxI 800 Immunoassay System. Clinical Chemistry and Laboratory Medicine, 2008, 46, 612-22.	2.3	10

#	Article	IF	Citations
55	Alternative antibody for the detection of CA19-9 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the AccessÂ® GI Monitor assay on the UniCelÂ® DxI 800 Immunoassay System. Clinical Chemistry and Laboratory Medicine, 2008, 46, 600-11.	2.3	15
56	Alternative antibody for the detection of CA125 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the AccessÂ® OV Monitor assay on the UniCelÂ® DxI 800 Immunoassay System. Clinical Chemistry and Laboratory Medicine, 2008, 46, 588-99.	2.3	10
57	Biological variability evaluation and comparison of three different methods for C-peptide measurement. Clinical Chemistry and Laboratory Medicine, 2008, 46, 1480-2.	2.3	0
58	Within-subject biological variation in disease: the case of tumour markers. Annals of Clinical Biochemistry, 2008, 45, 226-227.	1.6	8
59	Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. Endocrine-Related Cancer, 2007, 14, 473-482.	3.1	124
60	An Italian program of External Quality Control for chromogranin A (CgA) assay: performance evaluation of CgA determination. Clinical Chemistry and Laboratory Medicine, 2007, 45, 1244-50.	2.3	23
61	Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast Cancer Research and Treatment, 2007, 101, 355-365.	2.5	130
62	REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Research and Treatment, 2006, 100, 229-235.	2.5	666
63	The Combination of the Selective Cyclooxygenase-2 Inhibitor Celecoxib with Weekly Paclitaxel Is a Safe and Active Second-Line Therapy for Non-Small Cell Lung Cancer. Cancer Journal (Sudbury, Mass), 2005, 11, 209-216.	2.0	31
64	Biological Variation of Total Prostate-Specific Antigen: A Survey of Published Estimates and Consequences for Clinical Practice. Clinical Chemistry, 2005, 51, 1342-1351.	3.2	131
65	Tumor Markers in Breast Cancer – European Group on Tumor Markers Recommendations. Tumor Biology, 2005, 26, 281-293.	1.8	287
66	Reporting Recommendations for Tumor Marker Prognostic Studies. Journal of Clinical Oncology, 2005, 23, 9067-9072.	1.6	693
67	Biological variation of vascular endothelial growth factor. Clinical Chemistry and Laboratory Medicine, 2005, 43, 342-3.	2.3	7
68	Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK). Journal of the National Cancer Institute, 2005, 97, 1180-1184.	6.3	1,323
69	Biological variation of plasma chromogranin A. Clinical Chemistry and Laboratory Medicine, 2004, 42, 109-10.	2.3	16
70	Biomolecular features of clinical relevance in breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, S3-S14.	6.4	13
71	Prostate carcinoma and green tea: PSA-triggered basement membrane degradation and MMP-2 activation are inhibited by (?)epigallocatechin-3-gallate. International Journal of Cancer, 2004, 112, 787-792.	5.1	69
72	3rd EORTCâ€“NCI International Meeting on Cancer Molecular Markers: From Discovery to Clinical Practice. Expert Review of Molecular Diagnostics, 2004, 4, 431-433.	3.1	3

#	Article	IF	Citations
73	Prognostic and Predictive Indicators in Operable Breast Cancer. Clinical Breast Cancer, 2003, 3, 381-390.	2.4	30
74	Considerations on development, validation, application, and quality control of immuno(metric) biomarker assays in clinical cancer research: An EORTC-NCI working group report. International Journal of Oncology, 2003, 23, 1715.	3.3	8
75	Thrombospondin-1 and -2 in Node-Negative Breast Cancer: Correlation with Angiogenic Factors, p53, Cathepsin D, Hormone Receptors and Prognosis. Oncology, 2001, 60, 72-80.	1.9	34
76	Quantitative measurement of soluble cytokeratin fragments in tissue cytosol of 599 node negative breast cancer patients: a prognostic marker possibly associated with apoptosis. Breast Cancer Research and Treatment, 2000, 59, 211-221.	2.5	19
77	Percent free prostate-specific antigen in assessing the probability of prostate cancer under optimal analytical conditions. Clinical Chemistry, 1998, 44, 2462-2470.	3.2	13
78	Tissue Polypeptide Antigen as a Putative Indicator of Apoptosis. Clinical Chemistry, 1998, 44, 2002-2003.	3.2	6
79	Co-determination of the angiogenic factors thymidine phosphorylase and vascular endothelial growth factor in node-negative breast cancer: prognostic implications. Angiogenesis, 1997, 1, 71-83.	7.2	26
80	Preliminary Results of Clinical Evaluation of the Free/Total Prostate-Specific Antigen Ratio in a Multicentric Study. Tumori, 1996, 82, 543-549.	1.1	4
81	Comparison between single saturating dose ligand binding assay and enzyme immunoassay for low-salt extractable oestrogen and progesterone receptors in breast cancer: A multicentre study. European Journal of Cancer & Clinical Oncology, 1991, 27, 996-1002.	0.7	8
82	Tissue polypeptide antigen in tumor cytosol: A new prognostic indicator in primary breast cancer. Breast Cancer Research and Treatment, 1990, 17, 15-21.	2.5	13
83	Is Tissue Polypeptide Antigen Still a Useful Tumor Marker in Breast Carcinoma? Comparison with Ca15.3 and Mca. Tumori, 1990, 76, 360-364.	1.1	13
84	Tumor Markers in Serum of Patients with Primary Squamous Cell Carcinoma of the Esophagus. Tumori, 1989, 75, 489-493.	1.1	12
85	A mucinous-like carcinoma-associated antigen (MCA) in the tissue and blood of patients with primary breast cancer. Cancer, 1989, 63, 490-495.	4.1	43
86	Tumor marker radioimmunoassays in gastric juice. Gastroenterology, 1988, 94, 1271-1275.	1.3	4
87	Carcinoembryonic Antigen, Ferritin, Tissue Polypeptide Antigen, and Ca15/3 in Breast Cancer: Relationship between Carcinoma and Normal Breast Tissue. International Journal of Biological Markers, 1986, 1, 33-38.	1.8	16
88	Carcinoembryonic antigen, ferritin, and tissue polypeptide antigen in serum and tissue. Relationship with the receptor content in breast carcinoma. Cancer, 1986, 57, 917-922.	4.1	32
89	Estrogen and Progesterone Receptors in Breast Carcinoma and in Nonmalignant Breast Tissue. Tumori, 1985, 71, 477-481.	1.1	5